Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Itay Moshkovits is active.

Publication


Featured researches published by Itay Moshkovits.


Nature Immunology | 2014

Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5–induced eosinophil development

Netali Ben Baruch-Morgenstern; Dana Shik; Itay Moshkovits; Michal Itan; Danielle Karo-Atar; Carine Bouffi; Patricia C. Fulkerson; Diana Rashkovan; Steffen Jung; Marc E. Rothenberg; Ariel Munitz

Eosinophilia is a hallmark characteristic of T helper type 2 (TH2) cell–associated diseases and is critically regulated by the central eosinophil growth factor interleukin 5 (IL-5). Here we demonstrate that IL-5 activity in eosinophils was regulated by paired immunoglobulin-like receptors PIR-A and PIR-B. Upon self-recognition of β2-microglobulin (β2M) molecules, PIR-B served as a permissive checkpoint for IL-5–induced development of eosinophils by suppressing the proapoptotic activities of PIR-A, which were mediated by the Grb2-Erk-Bim pathway. PIR-B–deficient bone marrow eosinophils underwent compartmentalized apoptosis, resulting in decreased blood eosinophilia in naive mice and in mice challenged with IL-5. Subsequently, Pirb−/− mice displayed impaired aeroallergen-induced lung eosinophilia and induction of lung TH2 cell responses. Collectively, these data uncover an intrinsic, self-limiting pathway regulating IL-5–induced expansion of eosinophils, which has broad implications for eosinophil-associated diseases.


Proceedings of the National Academy of Sciences of the United States of America | 2015

CD300f associates with IL-4 receptor α and amplifies IL-4–induced immune cell responses

Itay Moshkovits; Danielle Karo-Atar; Michal Itan; Hadar Reichman; Perri Rozenberg; Netali Morgenstern-Ben-Baruch; Dana Shik; Aroa Ejarque-Ortiz; Alon Y. Hershko; Linjie Tian; John E. Coligan; Joan Sayós; Ariel Munitz

Significance IL-4 receptor (R) α is a critical component in IL-4– and IL-13–mediated signaling and subsequent effector functions such as those observed in allergy. Thus, it is a primary therapeutic target in diseases such as atopic dermatitis and asthma. Despite extensive studies, it is unknown whether an additional receptor system exists that may act to amplify IL-4Rα signaling and subsequent IL-4/IL-13–induced responses. We now report that CD300f is physically associated with IL-4Rα and potently amplifies IL-4Rα–induced responses in vitro and in vivo. Our results establish CD300f as a previously unidentified IL-4Rα coreceptor. To the best of our knowledge, this is the first report of an additional receptor that serves to amplify the IL-4 signaling pathway. IL-4 receptor (R) α, the common receptor chain for IL-4 and IL-13, is a critical component in IL-4– and IL-13–mediated signaling and subsequent effector functions such as those observed in type 2 inflammatory responses. Nonetheless, the existence of intrinsic pathways capable of amplifying IL-4Rα–induced responses remains unknown. In this study, we identified the myeloid-associated Ig receptor CD300f as an IL-4–induced molecule in macrophages. Subsequent analyses demonstrated that CD300f was colocalized and physically associated with IL-4Rα. Using Cd300f−/− cells and receptor cross-linking experiments, we established that CD300f amplified IL-4Rα–induced responses by augmenting IL-4/IL-13–induced signaling, mediator release, and priming. Consistently, IL-4– and aeroallergen-treated Cd300f−/− mice displayed decreased IgE production, chemokine expression, and inflammatory cell recruitment. Impaired responses in Cd300f−/− mice were not due to the inability to generate a proper Th2 response, because IL-4/IL-13 levels were markedly increased in allergen-challenged Cd300f−/− mice, a finding that is consistent with decreased cytokine consumption. Finally, CD300f expression was increased in monocytes and eosinophils obtained from allergic rhinitis patients. Collectively, our data highlight a previously unidentified role for CD300f in IL-4Rα–induced immune cell responses. These data provide new insights into the molecular mechanisms governing IL-4Rα–induced responses, and may provide new therapeutic tools to target IL-4 in allergy and asthma.


American Journal of Respiratory Cell and Molecular Biology | 2013

Paired immunoglobulin-like receptor-B inhibits pulmonary fibrosis by suppressing profibrogenic properties of alveolar macrophages.

Danielle Karo-Atar; Itay Moshkovits; Oliver Eickelberg; Melanie Königshoff; Ariel Munitz

Macrophages are lung-resident cells that play key roles in fibrosis. Surprisingly, pathways that inhibit macrophage functions, especially in idiopathic pulmonary fibrosis (IPF), receive little attention. The cell-surface molecule paired immunoglobulin-like receptor B (PIR-B) can suppress macrophage activation. However, its role in pulmonary fibrosis remains unknown. We sought to define the role of PIR-B in IPF. The expression of PIR-B was assessed (by quantitative PCR and flow cytometry) after bleomycin treatment. Differential cell counts, histopathology, and profibrogenic-mediator expression, for example, collagen, α-smooth muscle actin, resistin-like molecule-α (Relm-α), matrix metalloproteinase (MMP)-12, and tissue inhibitor of metalloproteinase (TIMP)-1, were determined (by ELISA quantitative PCR and flow cytometry) in the lungs of wild-type and Pirb(-/-) mice after bleomycin or IL-4 treatment. Bone marrow-derived wild-type and Pirb(-/-) macrophages were stimulated with IL-4 and assessed for Relm-α and MMP-12 expression. PIR-B was up-regulated in lung myeloid cells after bleomycin administration. Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-α, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages. Increased profibrogenic mediator expression in Pirb(-/-) mice was not attributable to increased IL-4/IL-13 concentrations, suggesting that PIR-B negatively regulates IL-4-induced macrophage activation. Indeed, IL-4-treated Pirb(-/-) mice displayed increased Relm-α expression and Relm-α(+) macrophage concentrations. IL-4-activated Pirb(-/-) macrophages displayed increased Relm-α and MMP-12 induction. Finally, leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3)/immunoglobulin-like transcript-5, the human PIR-B orthologue, was expressed and up-regulated in lung biopsies from patients with IPF. Our results establish a key role for PIR-B in IPF, likely via the regulation of macrophage activation. Therefore, PIR-B/LILRB3 may offer a possible target for suppressing macrophage profibrogenic activity in IPF.


Allergy | 2014

Interleukin-33 requires CMRF35-like molecule-1 expression for induction of myeloid cell activation.

Dana Shik; Itay Moshkovits; Danielle Karo-Atar; Hadar Reichman; Ariel Munitz

IL‐33 is a potent activator of various cells involved in allergic inflammation, including eosinophils and mast cells. Despite its critical role in Th2 disease settings, endogenous molecular mechanisms that may regulate IL‐33‐induced responses remain to be defined. We have recently shown that eosinophils express CMRF35‐like molecule (CLM)‐1. Yet, the role of CLM‐1 in regulating eosinophil functions is still elusive.


Mucosal Immunology | 2017

A key requirement for CD300f in innate immune responses of eosinophils in colitis

Itay Moshkovits; Hadar Reichman; Danielle Karo-Atar; P Rozenberg; E Zigmond; N Ben Baruch-Morgenstern; M Lampinen; M Carlson; Michal Itan; Lee A. Denson; C Varol; Ariel Munitz

Eosinophils are traditionally studied in the context of type 2 immune responses. However, recent studies highlight key innate immune functions for eosinophils especially in colonic inflammation. Surprisingly, molecular pathways regulating innate immune activities of eosinophil are largely unknown. We have recently shown that the CD300f is highly expressed by colonic eosinophils. Nonetheless, the role of CD300f in governing innate immune eosinophil activities is ill-defined. RNA sequencing of 162 pediatric Crohn’s disease patients revealed upregulation of multiple Cd300 family members, which correlated with the presence of severe ulcerations and inflammation. Increased expression of CD300 family receptors was also observed in active ulcerative colitis (UC) and in mice following induction of experimental colitis. Specifically, the expression of CD300f was dynamically regulated in monocytes and eosinophils. Dextran sodium sulfate (DSS)-treated Cd300f−/− mice exhibit attenuated disease activity and histopathology in comparison with DSS-treated wild type (WT). Decreased disease activity in Cd300f−/− mice was accompanied with reduced inflammatory cell infiltration and nearly abolished production of pro-inflammatory cytokines. Monocyte depletion and chimeric bone marrow transfer experiments revealed a cell-specific requirement for CD300f in innate immune activation of eosinophils. Collectively, we uncover a new pathway regulating innate immune activities of eosinophils, a finding with significant implications in eosinophil-associated gastrointestinal diseases.


Clinical & Experimental Allergy | 2017

IL‐33 and IgE stimulate mast cell production of IL‐2 and regulatory T cells expansion in allergic dermatitis

Pazit Salamon; Irit Shefler; Itay Moshkovits; Ariel Munitz; Deborah Horwitz Klotzman; Yoseph A. Mekori; Alon Y. Hershko

We have previously shown that mast cells (MCs) suppress chronic allergic dermatitis in mice. The underlying mechanism involves MC‐derived IL‐2, which supports regulatory T cell (Treg) response at the site of inflammation. However, it is not clear what are the factors that drive MCs to produce IL‐2.


Journal of Molecular Medicine | 2016

Erratum to: A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents

Michal Caspi; Anastasia Firsow; Raja Rajkumar; Nir Skalka; Itay Moshkovits; Ariel Munitz; Metsada Pasmanik-Chor; Hagar Greif; Dalia Megiddo; Revital Kariv; Daniel W. Rosenberg; Rina Rosin-Arbesfeld

A large number of human diseases are caused by nonsense mutations. These mutations result in premature protein termination and the expression of truncated, usually nonfunctional products. A promising therapeutic strategy for patients suffering from premature termination codon (PTC)-mediated disorders is to suppress the nonsense mutation and restore the expression of the affected protein. Such a suppression approach using specific antibiotics and other read-through promoting agents has been shown to suppress PTCs and restore the production of several important proteins. Here, we report the establishment of a novel, rapid, and very efficient method for screening stop-codon read-through agents. We also show that, in both mammalian cells and in a transgenic mouse model, distinct members of the macrolide antibiotic family can induce read-through of disease-causing stop codons leading to reexpression of several key proteins and to reduced disease phenotypes. Taken together, our results may help in the identification and characterization of well-needed customized pharmaceutical PTC suppression agents. Key messages & Establishment of a flow cytometry-based reporter assay to identify nonsense mutation read-through agents. & Macrolide antibiotics can induce read-through of diseasecausing stop codons. & Macrolide-induced protein restoration can alleviate disease-like phenotypes.


PLOS ONE | 2016

Natural Killer Receptor 1 Dampens the Development of Allergic Eosinophilic Airway Inflammation.

Shirin Elhaik Goldman; Itay Moshkovits; Avishai Shemesh; Ayelet Filiba; Yevgeny Tsirulsky; Elena Vronov; Marilou Shagan; Ron N. Apte; D aniel Benharroch; Danielle Karo-Atar; Ron Dagan; Ariel Munitz; Yaffa Mizrachi Nebenzahl; Angel Porgador

The function of NCR1 was studied in a model of experimental asthma, classified as a type 1 hypersensitivity reaction, in mice. IgE levels were significantly increased in the serum of OVA immunized NCR1 deficient (NCR1gfp/gfp) mice in comparison to OVA immunized wild type (NCR1+/+) and adjuvant immunized mice. Histological analysis of OVA immunized NCR1gfp/gfp mice revealed no preservation of the lung structure and overwhelming peribronchial and perivascular granulocytes together with mononuclear cells infiltration. OVA immunized NCR+/+ mice demonstrated preserved lung structure and peribronchial and perivascular immune cell infiltration to a lower extent than that in NCR1gfp/gfp mice. Adjuvant immunized mice demonstrated lung structure preservation and no immune cell infiltration. OVA immunization caused an increase in PAS production independently of NCR1 presence. Bronchoalveolar lavage (BAL) revealed NCR1 dependent decreased percentages of eosinophils and increased percentages of lymphocytes and macrophages following OVA immunization. In the OVA immunized NCR1gfp/gfp mice the protein levels of eosinophils’ (CCL24) and Th2 CD4+ T-cells’ chemoattractants (CCL17, and CCL24) in the BAL are increased in comparison with OVA immunized NCR+/+ mice. In the presence of NCR1, OVA immunization caused an increase in NK cells numbers and decreased NCR1 ligand expression on CD11c+GR1+ cells and decreased NCR1 mRNA expression in the BAL. OVA immunization resulted in significantly increased IL-13, IL-4 and CCL17 mRNA expression in NCR1+/+ and NCR1gfp/gfp mice. IL-17 and TNFα expression increased only in OVA-immunized NCR1+/+mice. IL-6 mRNA increased only in OVA immunized NCR1gfp/gfp mice. Collectively, it is demonstrated that NCR1 dampens allergic eosinophilic airway inflammation.


Frontiers in Immunology | 2018

The Critical Role of Chemokine (C–C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis

Debby Reuveni; Yael Gore; Patrick S.C. Leung; Yael Lichter; Itay Moshkovits; Ayelet Kaminitz; Eli Brazowski; Eric Lefebvre; Pamela Vig; Chen Varol; Zamir Halpern; Oren Shibolet; M. E. Gershwin; Ehud Zigmond

The therapy of primary biliary cholangitis (PBC) has lagged behind other autoimmune diseases despite significant improvements in our understanding of both immunological and molecular events that lead to loss of tolerance to the E2 component of pyruvate dehydrogenase, the immunodominant autoepitope of PBC. It is well known that Ly6Chi monocytes are innate immune cells infiltrating inflammatory sites that are dependent on the expression of C–C motif chemokine receptor 2 (CCR2) for emigration from bone marrow. Importantly, humans with PBC have a circulating monocyte pro-inflammatory phenotype with macrophage accumulation in portal tracts. We have taken advantage of an inducible chemical xenobiotic model of PBC and recapitulated the massive infiltration of monocytes to portal areas. To determine the clinical significance, we immunized both CCR2-deficient mice and controls with 2OA-BSA and noted that CCR2 deficiency is protective for the development of autoimmune cholangitis. Importantly, because of the therapeutic potential, we focused on inhibiting monocyte infiltration through the use of cenicriviroc (CVC), a dual chemokine receptor CCR2/CCR5 antagonist shown to be safe in human trials. Importantly, treatment with CVC resulted in amelioration of all aspects of disease severity including serum total bile acids, histological severity score, and fibrosis stage. In conclusion, our results indicate a major role for Ly6Chi monocytes and for CCR2 in PBC pathogenesis and suggest that inhibition of this axis by CVC should be explored in humans through the use of clinical trials.


The Journal of Allergy and Clinical Immunology | 2015

The Mechanisms Involved in IL-2 Production By Regulatory Mast Cells in Chronic Allergic Dermatitis

Alon Y. Hershko; Itay Moshkovits; Ariel Munitz; Yoseph A. Mekori; Pazit Salamon

Collaboration


Dive into the Itay Moshkovits's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Steffen Jung

Weizmann Institute of Science

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marc E. Rothenberg

Cincinnati Children's Hospital Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge